Clinical Research Directory

Inclusion Criteria: 1. Adults ≥ 18 years old 2. Signed written consent form 3. Primary or secondary thrombotic APS according to 2023 ACR/EULAR classification criteria 4. aPL antibodies loss of LA, aCL, and aβ2GPI antibodies - defined as a normalised level (\< 99th percentile) - in at least two consecutive measurements with at least 12 months between each measurement including one negative measurement within the 3 months preceding inclusion 5. Long term (\>12 months) VKAs therapy Exclusion Criteria: 1. History of severe venous thrombosis. Severe venous thrombosis including massive pulmonary embolism; chronic thromboembolic pulmonary hypertension; hepatic, mesenteric, renal and/or cerebral venous thrombosis 2. History of arterial thrombosis 3. History of recurrent venous thrombosis while receiving VKAs 4. History of catastrophic antiphospholipid syndrome (CAPS) 5. Triple aPL positivity 6. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 for each VKAs medicinal product 7. Malignant hypertension 8. Severe hepatic impairment 9. Active malignancy 10. Presence of a mechanical heart valve or any other medical condition requiring anticoagulation with a VKA 11. Pregnancy or breastfeeding 12. Subject deprived of freedom, subject under a legal protective measure 13. No affiliation to any health insurance system 14. Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)